Vera Therapeutics (VERA) Capital Expenditures (2020 - 2026)

Vera Therapeutics (VERA) has 6 years of Capital Expenditures data on file, last reported at $23000.0 in Q1 2026.

• Quarterly Capital Expenditures fell 87.7% year-over-year to $23000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $466000.0 (down 59.79% YoY) and the FY2025 annual result came in at $630000.0, down 35.19% from the prior year.
• Capital Expenditures eased to $23000.0 in Q1 2026, from $102000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $645000.0 in Q4 2024 to a low of $6000.0 in Q2 2022.
• A 5-year average of $145833.3 and a median of $95500.0 in 2024 frame the typical range for Capital Expenditures.
• Annual changes were most pronounced in 2024 — Capital Expenditures jumped 923.81% — and 2026, when it tumbled 87.7%.
• Tracing VERA's Capital Expenditures over 5 years: stood at $38000.0 in 2022, then jumped by 65.79% to $63000.0 in 2023, then jumped by 923.81% to $645000.0 in 2024, then tumbled by 84.19% to $102000.0 in 2025, then sank by 77.45% to $23000.0 in 2026.
• The last three Capital Expenditures figures came in at $23000.0 (Q1 2026), $102000.0 (Q4 2025), and $133000.0 (Q3 2025), per Business Quant data.